Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 11 |
| List of Tables | 11 | 1 |
| List of Figures | 12 | 1 |
| Introduction | 13 | 1 |
| Global Markets Direct Report Coverage | 13 | 1 |
| Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Overview | 14 | 1 |
| Therapeutics Development | 15 | 2 |
| Pipeline Products for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Overview | 15 | 1 |
| Pipeline Products for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Comparative Analysis | 16 | 1 |
| Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Therapeutics under Development by Companies | 17 | 3 |
| Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Therapeutics under Investigation by Universities/Institutes | 20 | 1 |
| Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Products Glance | 21 | 3 |
| Late Stage Products | 21 | 1 |
| Clinical Stage Products | 22 | 1 |
| Early Stage Products | 23 | 1 |
| Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Products under Development by Companies | 24 | 4 |
| Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Products under Investigation by Universities/Institutes | 28 | 1 |
| Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Companies Involved in Therapeutics Development | 29 | 41 |
| 4SC AG | 29 | 1 |
| AbbVie Inc | 30 | 1 |
| Acetylon Pharmaceuticals, Inc. | 31 | 1 |
| Actinium Pharmaceuticals, Inc. | 32 | 1 |
| ADC Therapeutics Sarl | 33 | 1 |
| Affimed GmbH | 34 | 1 |
| Amgen Inc. | 35 | 1 |
| Arno Therapeutics, Inc. | 36 | 1 |
| Bellicum Pharmaceuticals, Inc. | 37 | 1 |
| Bristol-Myers Squibb Company | 38 | 1 |
| Celgene Corporation | 39 | 1 |
| Cell Medica Limited | 40 | 1 |
| Cellular Biomedicine Group, Inc. | 41 | 1 |
| Constellation Pharmaceuticals, Inc. | 42 | 1 |
| Curis, Inc. | 43 | 1 |
| Faron Pharmaceuticals Oy | 44 | 1 |
| Gamida Cell Ltd. | 45 | 1 |
| Incyte Corporation | 46 | 1 |
| Merck &Co., Inc. | 47 | 1 |
| Merck KGaA | 48 | 1 |
| Mesoblast Limited | 49 | 1 |
| Millennium Pharmaceuticals Inc | 50 | 1 |
| Mirati Therapeutics Inc. | 51 | 1 |
| Molecular Templates Inc. | 52 | 1 |
| NantKwest, Inc. | 53 | 1 |
| Ono Pharmaceutical Co., Ltd. | 54 | 1 |
| Pfizer Inc. | 55 | 1 |
| Philogen S.p.A. | 56 | 1 |
| Polyphor Ltd. | 57 | 1 |
| Rich Pharmaceuticals, Inc. | 58 | 1 |
| Seattle Genetics, Inc. | 59 | 1 |
| Selvita S.A. | 60 | 1 |
| Sigma-Tau S.p.A. | 61 | 1 |
| Spectrum Pharmaceuticals, Inc. | 62 | 1 |
| Stemline Therapeutics, Inc. | 63 | 1 |
| Taiwan Liposome Company, Ltd. | 64 | 1 |
| Takeda Pharmaceutical Company Limited | 65 | 1 |
| TG Therapeutics, Inc. | 66 | 1 |
| Theravectys SA | 67 | 1 |
| TRACON Pharmaceuticals, Inc. | 68 | 1 |
| Trillium Therapeutics Inc. | 69 | 1 |
| Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Therapeutics Assessment | 70 | 17 |
| Assessment by Monotherapy Products | 70 | 1 |
| Assessment by Combination Products | 71 | 1 |
| Assessment by Target | 72 | 5 |
| Assessment by Mechanism of Action | 77 | 6 |
| Assessment by Route of Administration | 83 | 2 |
| Assessment by Molecule Type | 85 | 2 |
| Drug Profiles | 87 | 270 |
| (INCB-039110 + INCB-040093) Drug Profile | 87 | 1 |
| ADCT-301 Drug Profile | 88 | 1 |
| AFM-13 Drug Profile | 89 | 4 |
| Alocrest Drug Profile | 93 | 2 |
| AR-42 Drug Profile | 95 | 2 |
| avelumab Drug Profile | 97 | 5 |
| azacitidine Drug Profile | 102 | 5 |
| balixafortide Drug Profile | 107 | 2 |
| BC-8Y90 Drug Profile | 109 | 1 |
| BMS-986016 Drug Profile | 110 | 2 |
| BPX-501 Drug Profile | 112 | 4 |
| brentuximab vedotin Drug Profile | 116 | 24 |
| CBM-C30.1 Drug Profile | 140 | 1 |
| Cellular Immunotherapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma Drug Profile | 141 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 142 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 143 | 1 |
| Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas Drug Profile | 144 | 1 |
| Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas Drug Profile | 145 | 1 |
| Cellular Immunotherapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Drug Profile | 146 | 1 |
| Cellular Immunotherapy to Target GM-CSF for Solid Tumor and Hematological Cancer Drug Profile | 147 | 1 |
| Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection Drug Profile | 148 | 1 |
| Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases Drug Profile | 149 | 1 |
| Cellular Immunotherapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology Drug Profile | 150 | 1 |
| CMD-003 Drug Profile | 151 | 2 |
| CPI-0610 Drug Profile | 153 | 1 |
| CUDC-907 Drug Profile | 154 | 5 |
| Epstein-Barr virus vaccine Drug Profile | 159 | 1 |
| Ferritarg Drug Profile | 160 | 1 |
| FP-1305 Drug Profile | 161 | 2 |
| haNK Program Drug Profile | 163 | 1 |
| ibrutinib Drug Profile | 164 | 25 |
| INCB-40093 Drug Profile | 189 | 1 |
| Indimitecan Drug Profile | 190 | 1 |
| Indotecan hydrochloride Drug Profile | 191 | 1 |
| Iomab-B Drug Profile | 192 | 5 |
| ipilimumab Drug Profile | 197 | 8 |
| ixazomib citrate Drug Profile | 205 | 9 |
| lirilumab Drug Profile | 214 | 4 |
| MK-2206 Drug Profile | 218 | 3 |
| mocetinostat Drug Profile | 221 | 5 |
| Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections Drug Profile | 226 | 1 |
| MPC-CBE Drug Profile | 227 | 2 |
| MT-17000 Drug Profile | 229 | 1 |
| NiCord Drug Profile | 230 | 3 |
| nivolumab Drug Profile | 233 | 28 |
| NL-101 Drug Profile | 261 | 2 |
| ONX-0801 Drug Profile | 263 | 2 |
| pembrolizumab Drug Profile | 265 | 31 |
| PF-06801591 Drug Profile | 296 | 1 |
| PNK-007 Drug Profile | 297 | 1 |
| procarbazine hydrochloride Drug Profile | 298 | 1 |
| radretumab Drug Profile | 299 | 2 |
| resminostat Drug Profile | 301 | 10 |
| ricolinostat Drug Profile | 311 | 8 |
| RP-323 Drug Profile | 319 | 2 |
| ruxolitinib phosphate Drug Profile | 321 | 12 |
| sapanisertib Drug Profile | 333 | 3 |
| SEA-CD40 Drug Profile | 336 | 1 |
| SEL-24B489 Drug Profile | 337 | 1 |
| SL-101 Drug Profile | 338 | 1 |
| SL-501 Drug Profile | 339 | 1 |
| Small Molecule to Inhibit ADAM-10 for Hodgkin Lymphoma Drug Profile | 340 | 1 |
| temsirolimus Drug Profile | 341 | 2 |
| TGR-1202 Drug Profile | 343 | 7 |
| TRC-102 Drug Profile | 350 | 2 |
| TTI-621 Drug Profile | 352 | 3 |
| Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma Drug Profile | 355 | 1 |
| vinorelbine tartrate Drug Profile | 356 | 1 |
| Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Dormant Projects | 357 | 4 |
| Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Discontinued Products | 361 | 1 |
| Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Product Development Milestones | 362 | 13 |
| Featured News &Press Releases | 362 | 1 |
| Jul 18, 2016: Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood | 362 | 2 |
| Jul 06, 2016: Takeda Receives European Commission Approval of ADCETRIS (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma | 364 | 1 |
| Jun 21, 2016: Rich Pharmaceuticals Retains Theradex Systems To Help Advance Its Hodgkin Lymphoma Indication | 364 | 1 |
| Jun 10, 2016: New Data on Bristol-Myers Squibbs Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial | 365 | 1 |
| Jun 09, 2016: Bristol-Myers Squibb to Present New Data on Opdivo (nivolumab) at the 21st Congress of the European Hematology Association | 366 | 1 |
| Jun 06, 2016: KEYTRUDA (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087 | 367 | 1 |
| May 31, 2016: Mundipharma EDO Announces First-in-human Clinical Trial of its Lead Compound, EDO-S101 | 368 | 1 |
| May 27, 2016: Takeda Receives Positive CHMP Opinion for ADCETRIS (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma | 369 | 1 |
| May 17, 2016: Opdivo (nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transplantation Brentuximab Vedotin by the FDA | 370 | 2 |
| Apr 21, 2016: Affimed Presents Data on AFM13-mediated Innate/Adaptive Immune Crosstalk at the AACR Annual Meeting 2016 | 372 | 1 |
| Apr 18, 2016: Seattle Genetics Highlights Data on ADCETRIS at the American Association for Cancer Research Annual Meeting | 373 | 1 |
| Apr 18, 2016: Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA (pembrolizumab) in Classical Hodgkin Lymphoma | 373 | 1 |
| Apr 14, 2016: U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb s Supplemental Biologics License Application for Opdivo (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients | 374 | 1 |
| Mar 30, 2016: European Medicines Agency Validates Bristol-Myers Squibb s Application for Opdivo (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients | 374 | 1 |
| Appendix | 375 | 2 |
| Methodology | 375 | 1 |
| Coverage | 375 | 1 |
| Secondary Research | 375 | 1 |
| Primary Research | 375 | 1 |
| Expert Panel Validation | 375 | 1 |
| Contact Us | 375 | 1 |
| Disclaimer | 376 | 1 |